Protein structure Source: Generate Biomedicine

With the incredibly rapid advances in artificial intelligence and machine learning (AI/ML) models of late there is growing potential for an exponential impact on R&D, especially in the field of oncology.

While some observers may well be sceptical or wary, there are ways we can use these tools for greater scientific good by generating better, smarter drug designs rather than just mere productivity gains.

As more companies are exploring difficult or intractable targets, the need for enhanced computational power is increasing.

In our latest post, we combine some amazing discovery findings from the upcoming American Society of Hematology (ASH) meeting with a story around the evolution of computational models and how they can help some brave companies and researchers develop new medicines with a difference rather than yet another me-too drug.

Are you ready for a tempestuous revolution rather than a slow paced evolution?

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by